Skip to main content
Premium Trial:

Request an Annual Quote

Xention to Study Biomarkers for AF Network

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Xention will study biomarkers to support the European Network for Translational Research in Atrial Fibrillation (EUTRAF), which has received a €12 million ($16.7 million) grant from the European Union to research this disorder, the company said today.

Under the agreement, Cambridge, UK-based Xention will characterize molecular biomarkers of abnormal function of ion channels linked to atrial fibrillation. It also will validate new ion channels for their therapeutic potential and will identify pharmacological tools for validating such channels.

EUTRAF is a consortium of universities and biotechnology and pharmaceutical firms around Europe that have joined together in a five-year AF study with the aim of improving diagnosis, prevention, and treatment for the disease, which affects around 6 million Europeans, or around one to two percent of the population.

The company said that AF increases the risk of stroke five-fold and it is responsible for one in five strokes, with many of these being fatal or crippling.

The Scan

Should've Been Spotted Sooner

Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier.

For Martian Fuel

Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo.

To Boost Rapid Testing

The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests.

PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing

In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.